Sarepta Therapeutics To Present Results From EMERGENE Phase 3 Study On Expression Of SGCB And Safety Following Bidridistrogene Xeboparvovec Treatment In Patients With LGMD2E/R4, At WMS 2025 Congress
Author: Benzinga Newsdesk | October 03, 2025 07:36am